DERIVATIVE LIABILITIES
9 Months Ended 12 Months Ended
Sep. 30, 2015
Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Derivative Instruments and Hedging Activities Disclosure [Text Block]
NOTE 8 — DERIVATIVE LIABILITIES
 
Series A, B and C Preferred Stock Conversion Options
The conversion features embedded in the Company’s Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock were bifurcated as they were not considered to be clearly and closely related to the host agreement and were accounted for as a derivative liabilities.
 
As disclosed above, during the nine months ended September 30, 2015, all issued and outstanding shares of the Company’s Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock were converted into shares of the Company’s common stock. As a result, on the date of conversion the Company re-measured the fair value of each of the conversion features, recorded the change in fair value of the conversion feature in other expense on the condensed statements of operations, and reclassified the re-measured amount to stockholders’ equity.
 
Warrants to Purchase Common Stock
The warrants issued in connection with the Series A Financing, Series B Financing, and Series C Financing have been accounted for as derivative liabilities as each of the warrants contain a net cash settlement provision whereby, upon certain fundamental events, the holders could put the warrants back to the Company for cash.
 
On July 20, 2015, and effective June 11, 2015, the Company amended the warrants issued to investors on December 30, 2014, February 11, 2015 and February 24, 2015 in connection with issuances of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, respectively, to lower the exercise price from $20.00 per share to $11.50 per share, except for the warrants issued to certain family members of George Schmitt, which will retain an exercise price of $20.00 per share.
 
The table below sets forth a summary of changes in the fair value of the Company’s Level 3 derivative liabilities associated with the Series A Financing, Series B Financing, and Series C Financing for the nine months ended September 30, 2015:
 
 
 
Series A
 
 
Series B
 
 
Series B
 
 
Series C
 
 
 
 
 
 
Financing
 
 
Financing
 
 
(Related Party)
 
 
Financing
 
 
Total
 
Balance at January 1, 2015
 
$
270,000
 
 
$
 
 
$
 
 
$
 
 
$
270,000
 
Recognition of conversion feature liability
 
 
 
 
 
81,000
 
 
 
220,000
 
 
 
468,000
 
 
 
769,000
 
Recognition of warrant derivative liability
 
 
 
 
 
45,000
 
 
 
118,000
 
 
 
252,000
 
 
 
415,000
 
Reclassification to stockholders’ equity upon conversion
 
 
(150,000)
 
 
 
(54,000)
 
 
 
(220,000)
 
 
 
(245,000)
 
 
 
(669,000)
 
Change in fair value of derivative liabilities
 
 
(111,000)
 
 
 
(69,000)
 
 
 
(111,000)
 
 
 
(455,000)
 
 
 
(746,000)
 
Balance at September 30, 2015
 
$
9,000
 
 
$
3,000
 
 
$
7,000
 
 
$
20,000
 
 
$
39,000
 
 
The following are the key assumptions used in connection with the valuation of the conversion options associated with the Series A Financing, Series B Financing, and Series C Financing on the date of issuance, at December 31, 2014 and September 30, 2015:
 
 
 
Series A
 
 
Series B
 
 
Series B
 
 
Series C
 
 
 
Financing
 
 
Financing
 
 
(Related Party)
 
 
Financing
 
Date of issuance
 
 
12/31/2014
 
 
 
2/11/2015
 
 
 
2/24/2015
 
 
 
2/24/2015
 
Number of shares convertible into
 
 
750,000
 
 
 
350,000
 
 
 
845,000
 
 
 
1,800,000
 
Fair market value of stock
 
$
5.10
 
 
$
4.22
 
 
$
4.50
 
 
$
4.50
 
Conversion price
 
$
5.70
 
 
$
3.57
 
 
$
4.00
 
 
$
4.00
 
Volatility
 
 
131
%
 
 
143.4
%
 
 
143.4
%
 
 
143.4
%
Risk-free interest rate
 
 
0.25
%
 
 
0.24
%
 
 
0.22
%
 
 
0.22
%
Expected dividend yield
 
 
7
%
 
 
7
%
 
 
7
%
 
 
7
%
Life of convertible preferred stock (years)
 
 
1
 
 
 
1
 
 
 
1
 
 
 
1
 
 
The following are the key assumptions used in connection with the valuation of the warrants associated with the Series A Financing, Series B Financing, and Series C Financing at December 31, 2014, their respective issuance dates, and September 30, 2015:
 
 
 
Series A
 
 
Series B
 
 
Series B
 
 
Series C
 
 
 
Financing
 
 
Financing
 
 
(Related Party)
 
 
Financing
 
Date of warrant
 
 
12/31/2014
 
 
 
2/11/2015
 
 
 
2/24/2015
 
 
 
2/24/2015
 
Number of shares underlying the warrants
 
 
37,500
 
 
 
17,500
 
 
 
42,250
 
 
 
90,000
 
Fair market value of stock
 
$
5.10
 
 
$
4.22
 
 
$
4.50
 
 
$
4.50
 
Exercise price
 
$
20.00
 
 
$
20.00
 
 
$
20.00
 
 
$
20.00
 
Volatility
 
 
112.9
%
 
 
120.6
%
 
 
115.8
%
 
 
115.8
%
Risk-free interest rate
 
 
0.96
%
 
 
0.90
%
 
 
0.90
%
 
 
0.90
%
Expected dividend yield
 
 
 
 
 
 
 
 
 
 
 
 
Warrant life (years)
 
 
5
 
 
 
5
 
 
 
5
 
 
 
5
 
  
 
 
Series A
 
 
Series B
 
 
Series B
 
 
Series C
 
 
 
Financing
 
 
Financing
 
 
(Related Party)
 
 
Financing
 
Number of shares underlying the warrants on September 30, 2015
 
 
37,500
 
 
 
17,500
 
 
 
42,250
 
 
 
90,000
 
Fair market value of stock
 
$
0.58
 
 
$
0.58
 
 
$
0.58
 
 
$
0.58
 
Exercise price
 
$
11.50
 
 
$
11.50
 
 
$
20.00
 
 
$
11.50
 
Volatility
 
 
119.9
%
 
 
119.7
%
 
 
119.5
%
 
 
119.5
%
Risk-free interest rate
 
 
1.03
%
 
 
1.03
%
 
 
1.03
%
 
 
1.03
%
Expected dividend yield
 
 
 
 
 
 
 
 
 
 
 
 
Warrant life (years)
 
 
4.25
 
 
 
4.35
 
 
 
4.40
 
 
 
4.40
 
 
August 2015 Underwritten Offering
On August 19, 2015, the Company closed its underwritten public offering of its Class A Units, Class B Units, Series C Warrants and Series D Warrants. The Company offered (i) 2,550,000 Class A Units, at a price of $1.00 per Class A Unit, each of which consists of one share of its common stock and 0.5 of a Series A Warrant to purchase one share of its common stock at an exercise price of $1.00 per warrant, (ii) 2,450,000 Class B Units, at a price of $0.99 per Class B Unit, each of which consists of one pre-funded Series B Warrant to purchase one share of its common stock and 0.5 of a Series A Warrant, (iii) 2,550,000 Series C Warrants, at a price of $0.01 per Series C Warrant, which is deemed to be included in the $1.00 price per Class A Unit, each to purchase one additional Class A Unit at an exercise price of $1.00, and (iv) 4,950,000 Series D Warrants, at a price of $0.01 per Series D Warrant, which is deemed to be included in the $0.99 price per Class B Unit, each to purchase one additional Class B Unit at an exercise price of $0.99. Each of the warrants issued in connection with the August 2015 underwritten offering have been accounted for as derivative liabilities as each of the warrants contain a net cash settlement provision whereby, upon certain fundamental events, the holders could put the warrants back to the Company for cash.
 
The table below sets forth a summary of changes in the fair value of the Company’s Level 3 derivative liabilities associated with the August 2015 underwritten offering for the nine months ended September 30, 2015:
 
 
 
Series A
 
Series B
 
Series C
 
Series D
 
Total
 
Balance at January 1, 2015
 
$
 
$
 
$
 
$
 
$
 
Recognition of warrant liability on issuance date
 
 
1,275,000
 
 
1,568,000
 
 
178,000
 
 
347,000
 
 
3,368,000
 
Reclassification of derivative liability to stockholders’ equity upon exercise
 
 
 
 
(1,197,000)
 
 
 
 
 
 
(1,197,000)
 
Change in fair value of derivative liabilities
 
 
(151,000)
 
 
(371,000)
 
 
(101,000)
 
 
(198,000)
 
 
(821,000)
 
Balance at September 30, 2015
 
$
1,124,000
 
$
 
$
77,000
 
$
149,000
 
$
1,350,000
 
 
The following are the key assumptions used in connection with the valuation of the warrants exercisable into common stock on the date of issuance and September 30, 2015:
 
 
 
Series A
 
Series B
 
Series C
 
Series D
 
Date of warrant
 
 
8/19/2015
 
 
8/19/2015
 
 
8/19/2015
 
 
8/19/2015
 
Number of shares underlying the warrants
 
 
2,500,000
 
 
2,450,000
 
 
2,550,000
 
 
4,950,000
 
Fair market value of stock
 
$
0.65
 
$
0.65
 
$
0.65
 
$
0.65
 
Exercise price
 
$
1.00
 
$
0.01
 
$
1.00
 
$
0.99
 
Volatility
 
 
121.4
%
 
121.4
%
 
125.4
%
 
125.4
%
Risk-free interest rate
 
 
1.03
%
 
1.03
%
 
0.30
%
 
0.30
%
Expected dividend yield
 
 
 
 
 
 
 
 
 
Warrant life (years)
 
 
5
 
 
5
 
 
0.25
 
 
0.25
 
 
 
 
Series A
 
Series B
 
Series C
 
Series D
 
Number of shares underlying the warrants on September 30, 2015
 
 
2,500,000
 
 
 
 
2,550,000
 
 
4,950,000
 
Fair market value of stock
 
$
0.58
 
 
 
$
0.58
 
$
0.58
 
Exercise price
 
$
1.00
 
 
 
$
1.00
 
$
0.99
 
Volatility
 
 
124.2
%
 
 
 
144.4
%
 
144.4
%
Risk-free interest rate
 
 
0.98
%
 
 
 
0.38
%
 
0.38
%
Expected dividend yield
 
 
 
 
 
 
 
 
 
Warrant life (years)
 
 
4.88
 
 
 
 
0.13
 
 
0.13
 
 
Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department and are approved by the Chief Financial Officer.
 
Level 3 Valuation Techniques:
 
Level 3 financial liabilities consist of the derivative liabilities for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company deems financial instruments which do not have fixed settlement provisions to be derivative instruments. In accordance with ASC Topic 480, Distinguishing Liabilities from Equity, the fair value of these warrants is classified as a liability on the Company’s Condensed Consolidated Balance Sheets because, according to the terms of the warrants, a fundamental transaction could give rise to an obligation of the Company to pay cash to its warrant holders. Such instruments do not have fixed settlement provisions and have also been recorded as derivative liabilities. Corresponding changes in the fair value of the derivative liabilities are recognized in earnings on the Company’s Condensed Consolidated Statements of Operations in each subsequent period.
 
The Company’s derivative liabilities are carried at fair value and were classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs. In order to calculate fair value, the Company uses a binomial model style simulation, as the value of certain features of the warrant derivative liabilities would not be captured by the standard Black-Scholes model. 
 
The following table sets forth a summary of the changes in the fair value of our Level 3 financial liabilities that are measured at fair value on a recurring basis:
 
 
 
Three Months Ended
 
Nine Months Ended
 
 
 
September 30,
 
September 30,
 
 
 
2015
 
2014
 
2015
 
2014
 
Beginning balance
 
$
320,000
 
$
-
 
$
270,000
 
$
-
 
Recognition of conversion feature liability
 
 
-
 
 
-
 
 
769,000
 
 
-
 
Recognition of warrant liability on issuance date
 
 
3,368,000
 
 
-
 
 
3,783,000
 
 
-
 
Reclassification to stockholders’ equity upon exercise
 
 
(1,196,000)
 
 
-
 
 
(1,866,000)
 
 
-
 
Change in fair value of derivative liabilities
 
 
(1,103,000)
 
 
-
 
 
(1,567,000)
 
 
-
 
Ending balance
 
$
1,389,000
 
$
-
 
$
1,389,000
 
$
-
 
11 — DERIVATIVE LIABILITIES
 
Series A Convertible Preferred Stock — Conversion Option
 
On December 30, 2014, the Company entered into a purchase agreement pursuant to which the Company sold to 31 Group, 750,000 of the Company’s Series A Convertible Preferred Stock (the “Preferred Stock”). The Preferred Stock are convertible, in whole or in part, at a conversion price equal to the lower of (i) $20.00 or (ii) 85% of the average of the five (5) lowest volume weighted average prices of the common stock during the twenty (20) consecutive trading day period ending the trading day immediately preceding the delivery of the applicable conversion notice. The conversion feature was bifurcated from the Preferred Stock as it was not considered to be clearly and closely related to the host agreement and is accounted for as a derivative liability.
 
Warrants to Purchase Common Stock
 
In connection with the issuance of Series A Convertible Preferred Stock, the Company issued warrants to purchase up to 37,500 shares of Common Stock (the “Warrants”). The Warrants have an exercise price of $20.00 per share (the “Exercise Price”). Warrants covering up to 37,500 shares of Common Stock are exercisable at any time on or before December 31, 2019. The Warrants are accounted for as derivative liability as they can be redeemed by the holder for fair market value upon certain fundamental transactions.
 
The table below sets forth a summary of changes in the fair value of the Company’s Level 3 derivative liabilities for the year ended December 31, 2014:
 
Balance at beginning of year
 
$
 
Additions to conversion option derivative liability at December 30, 2014
 
 
150,000
 
Additions to warrant derivative liability at December 30, 2014
 
 
120,000
 
Change in fair market value of the derivative liabilities
 
 
 
Balance at end of year
 
$
270,000
 
 
These instruments were valued using pricing models that incorporate the price of a share of Common Stock, volatility, risk free rate, dividend rate and estimated life. The Company computed the fair value using the Black-Scholes model as of December 30, 2014. There was no change in fair value of the instruments at December 31, 2014.
 
The following are the key assumptions used in connection with the valuation of the conversion option on the date of issuance and at December 31, 2014:
 
Number of preferred shares
 
 
750,000
 
Fair market value of stock
 
$
5.10
 
Conversion Price
 
$
5.70
 
Volatility
 
 
131
%
Risk-free interest rate
 
 
0.13
%
Expected dividend yield
 
 
0
%
Life of Convertible Preferred Stock (year)
 
 
1
 
Number of shares underlying the Warrants
 
 
37,500
 
Fair market value of stock
 
$
5.10
 
Exercise Price
 
$
20.00
 
Volatility
 
 
112.9
%
Risk-free interest rate
 
 
0.96
%
Expected dividend yield
 
 
0
%
Warrant life (years)
 
 
5
 
 
The risk-free rate is based on the rate for the U.S. Treasury note over the expected terms. The expected term is the full term of the warrant and preferred stock. Expected volatility is based on the average of the weekly share price changes over the shorter of the expected term or the period from the placement on London Stock Exchange’s AIM Market to the date of the grant.